The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi, is pulling the plug. Why? To prepare the way for Lemtrada, a multiple sclerosis treatment that is, essentially, Campath by another name.
The next 5 or 6 weeks look big for potential approvals of new drugs.
A potential new Isis Pharmaceuticals ($ISIS) "anti-sense" drug helped restore normal muscle function in mice suffering from a form of muscular dystrophy. Credit new research spearheaded by Genzyme and the University of Rochester Medical Center with achieving the breakthrough.
Stop, thief! That's what Teva Pharmaceuticals is saying to Genzyme, in a dispute over sales reps. It seems a former Teva sales manager who defected to Genzyme is accused of poaching his former co-workers.
Genzyme CEO David Meeker must be smiling today. Sanofi CEO Chris Viehbacher is taking a page out of the Roche reinvention playbook. Just as Roche has restructured its Big Pharma R&D efforts around Genentech, Sanofi's Viehbacher sees its research ops being transformed by Genzyme's biotech example.
It took four attempts, but UniQure's Glybera has been approved by the European Medicines Agency as the first gene therapy treatment in a Western nation.
The ongoing downsizing of Sanofi is about to claim the jobs of up to 2,000 R&D, manufacturing and support staffers in France, according to a report from Le Figaro.
Massachusetts Gov. Deval Patrick has incented biotech companies to move and grow in the state, but his $1 billion life sciences plan has failed to deliver on the ambitious jobs growth originally forecasted four years ago, The Boston Globe reports.
It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.
Sanofi is on track to find out whether its $20 billion deal for Genzyme will pay off with a near-term drug approval. The pharma giant says that Genzyme has submitted applications for the MS drug Lemtrada in both the U.S. and Europe. Bayer is partnered on the program.